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The benefit of lowering blood
pressure
Raised blood pressure is associated
with significant cardiovascular
morbidity and mortality, yet there is no
demarcated cut-off point of blood
pressure that clearly separates
normotensive from hypertensive
indiv iduals.  In fact,  f rom an
epidemiological perspective, new data
from one million adults, including 61
prospective observational trials, the
relationship of blood pressure is liniar
down to systolic blood pressure (SBP)
of 115 mmHg and a diastolic blood
pressure (DBP) of 75 mmHg.1
It is clear from this data, that for
every increase of 20 mmHg in systolic
pressure or 10 mmHg increase in
diastolic pressure, cardiovascular risk
is doubled (see Figure I).  This study
also demonstrates that if SBP can be
decreased by 20 mmHg or DBP
decreased by 10 mmHg, the
cardiovascular risk can be halved.
The message is clear:
Moreover, there is no blood pressure
threshold below which benefits cease,
down to the level of 115/75 mmHg.
Trea tment  op t ions  fo r
hypertension
Since 1993 [JNC V Repor t] ,
recommendations for the clinical
management of hypertension have
been made.
Figure 1: Relationship:  Blood pressure and cardiovascular risk:
Combination therapy for
hypertension
Lowering of Blood Pressure
is all-important.
T.O.D. = Target organ damage and the presence of other cardiovascular risk factors will increase the risk of any given blood
pressure level.








Initiate with any one of 5 drug
categories:  diuretics, beta-blockers,
ACE-I, ARB, calcium blockers.
JNC V and VI: Endorsed diuretics ±
beta-blockers.
JNC VII: Endorsed diuretics initially
and as part of any combination with
the other drug classes (beta-blockers,
ACE-I, ARB, calcium blockers) all
having demonstrated mortality and
morbidity benefits.
With inadequate response: Defined
as not reaching goal:
Three options remain:
1. Upward drug titration:  Increase
t h e  d o s e  o f  o n e  d r u g
(monotherapy) until a response or
until intolerable side effects.
2. Drug substitution: (sequential
monotherapy) rotate through all
five classes until the right drug is
found.  This is time-consuming.
3. Combination drug therapy:
Small doses of two drugs with
different modes of action are used.
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Today, many experts see to initiate
drug therapy for hypertension and not




1. To achieve goal blood
pressure in hypertension:
i. Combination therapy will be
needed in many (or most) hyper-
tensive patients to achieve optimal
blood pressure levels.  Fewer than
50% of hypertensive patients are
able to achieve their blood
pressure goal with the use of any
monotherapy.  In the USA, in less
than 30% of hypertensives goal
blood pressure is achieved.
Combining drugs may help to
increase the number of patients
reaching goal. Combination
therapy may also achieve other
objectives:
• improve patient compliance
by a simple once-a-day 
regimen
• reduce side effects
• reduce cost
ii. There is large heterogeneity in
response to drugs.  Combining two
different drugs from different
classes with different mechanisms
of action may address this problem.
iv. Use low-dose thiazide diuretics in
most patients as part of the
combination, as low-dose diuretics
have proven themselves in many
large trials.2
2. Stage two or  h igher
hypertension:
Blood pressure > 160/100 mmHg:
initiate combination therapy, simply
because it is less likely to respond
to a single drug.
3. Proteinuria:
Systolic blood pressure must be
reduced to < 125 mmHg,
combination therapy will be
necessary in most, if not all cases.
4. Diabetes mellitus:
SBP must be reduced < 130
mmHg. ACE-inhibitor/ARB is
indicated, but not likely to succeed
to reduce BP to goal  as
monotherapy.
5. Renal failure:
ACE-I/ARB will be part of it.2
Drug combinations in
hypertension:




B. ACE-I/ARB:+ Calcium antago-
nist (dihydropyridine; non-dihydro-
pyridine).
C. Beta-blocker: + Calcium antago-
nist (only dihydropyridine)4
The value of combination
therapy in hypertension:
A recently reported meta-analysis of
354 randomised trials published the
following results:5
i. All five categories of drugs
(diuretics, beta-blockers, ACE-
inhibitors, angiotensin receptor
blockers (ARB’s), calcium channel
blockers:
a. Produced similar reductions in
blood pressure: average 9.1 mmHg
reduction in systolic pressure, 5.5
mmHg in diastolic pressure when
given in standard doses and only
20% lower at HALF standard dose.
b. The drugs reduced blood pressure
from all pre-treatment levels (more
so from higher levels).
ii. Combinations of drugs at
HALF standard dose:
a. Blood pressure lowering effect of
combinations was additive.
b. Prevalence of adverse effects with
two drugs in combination at HALF
standard dose were less than
additive.
c. Adverse metabolic effects at HALF
standard dose were negligible.
Conclusion:
Combination low dose drug treatment
of hypertension increases efficacy and
reduces adverse effects.
ALLHAT-trial:
The ALLHAT-trial, the largest ever
randomised trial of antihypertensive
treatment reaffirmed the use of
combination therapy.6  It confirmed
the value of low-dose diuretics and,
in this trial, to reach goal blood
pressure of < 140/90 mmHg, 63% of all
participants needed a combination of
drugs (two or more drugs).  ALLHAT
does not give information about the
ideal combination of drugs required
to achieve optimal blood pressure
levels.
Recently the ASCOT-trial was
stopped due to the superior efficacy
of an ACE-inhibitor combined with a
calcium antagonist, above the
combination of a diuretic plus beta-
blocker.  These results have not been
published yet.
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